Celgene Corp (NASDAQ:CELG)
CAPS Rating:
A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
RSS Headlines
Fool UK
Recs
There are currently 150 shares in my "fund" with break-even of around 58.02 USD.
http://caps.fool.com/Blogs/fund-trades/687712.
http://twitter.com/portefeuillefun.